Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis

Date
2021
Author
Gardiner, Fergus W.
Kane, Stefan C.
Kebapcilar, Ayse
KEBAPCILAR, LEVENT
Kohari, Katherine
Kondrackiene, Jurate
Koster, Maria P. H.
Lee, Richard H.
Liu, Xiaohua
Locatelli, Anna
Macias, Rocio I. R.
Madazli, Riza
Majewska, Agata
Maksym, Kasia
Marathe, Jessica A.
Morton, Adam
Oudijk, Martijn A.
Oztekin, Deniz
Peek, Michael J.
Shennan, Andrew H.
Tribe, Rachel M.
Tripodi, Valeria
Ozterlemez, Naciye Turk
Vasavan, Tharni
Wong, L. F. Audris
Yinon, Yoav
Zhang, Qianwen
Zloto, Keren
Marschall, Hanns-Ulrich
Thornton, Jim
Chappell, Lucy C.
Williamson, Catherine
Ovadia, Caroline
Sajous, Jenna
Seed, Paul T.
Patel, Kajol
Williamson, Nicholas J.
Attilakos, George
Azzaroli, Francesco
Bacq, Yannick
Batsry, Linoy
Broom, Kelsey
Brun-Furrer, Romana
Bull, Laura
Chambers, Jenny
Cui, Yue
Ding, Min
Dixon, Peter H.
Estiu, Maria C.
Geenes, Victoria
Grymowicz, Monika
Gunaydin, Berrin
Hague, William M.
Haslinger, Christian
Hu, Yayi
Indraccolo, Ugo
Juusela, Alexander
Metadata
Show full item record
Abstract
Background Ursodeoxycholic acid is commonly used to treat intrahepatic cholestasis of pregnancy, yet its largest trial detected minimal benefit for a composite outcome (stillbirth, preterm birth, and neonatal unit admission). We aimed to examine whether ursodeoxycholic acid affects specific adverse perinatal outcomes.
URI
http://hdl.handle.net/20.500.12627/175476
https://doi.org/10.1016/s2468-1253(21)00074-1
Collections